Unlock stock picks and a broker-level newsfeed that powers Wall Street.
NasdaqGS - Delayed Quote USD

Certara, Inc. (CERT)

Compare
9.55
-0.23
(-2.35%)
At close: April 4 at 4:00:03 PM EDT
9.35
-0.20
(-2.09%)
After hours: April 4 at 5:59:40 PM EDT
Loading Chart for CERT
  • Previous Close 9.78
  • Open 9.30
  • Bid 9.34 x 800
  • Ask 9.66 x 800
  • Day's Range 9.21 - 9.72
  • 52 Week Range 9.21 - 19.18
  • Volume 3,371,526
  • Avg. Volume 1,422,290
  • Market Cap (intraday) 1.538B
  • Beta (5Y Monthly) 1.64
  • PE Ratio (TTM) --
  • EPS (TTM) -0.08
  • Earnings Date May 5, 2025 - May 9, 2025
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 14.22

Certara, Inc., together with its subsidiaries, provides technology-enabled services and software products for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solutions to predict pharmacokinetics and pharmacodynamics; Simcyp simulator, a mechanistic biosimulation platform for physiologically based pharmacokinetic simulation; Simcyp Discovery for scientists working on pre-investigational new drug and translational stages; Simcyp Biopharmaceutics for formulation scientists; and Simcyp Secondary Intelligence that integrates toxicology with quantitative analysis of large networks of molecular and functional biological changes. The company also provides Phoenix WinNonlin, a platform for non-compartmental analysis; Phoenix Hosted, which offers a secured and validated Certara Amazon Web Services workspace; Phoenix NLME, a population modeling and simulation software; and Pirana Modeling Workbench, which provides modelers with a structure to facilitate the iterative processes. In addition, it offers Chemaxon JChem engines, a chemical search engine; Chemaxon Compound Registration, which supports a streamlined lead optimization process workflow; Chemaxon Design Hub, a design and tracking platform for drug discovery teams and their external collaborators; Certara D360 software, a scientific informatics system for small molecule and biologics discovery research; and Chemaxon Marvin, a chemical drawing tool. Further, the company provides pinnacle 21, a cloud-based platform for clinical data automation, standardization, and validation; Pinnacle 21 Data Exchange to define data standards and specifications; Metadata Repository that enables study design using controlled and standardized data; CoAuthor software, which creates and assembles regulatory submissions and medical publications; and GlobalSubmit, a submissions management software. Certara Inc. was founded in 2008 and is headquartered in Radnor, Pennsylvania.

www.certara.com

1,487

Full Time Employees

December 31

Fiscal Year Ends

Recent News: CERT

View More

Performance Overview: CERT

Trailing total returns as of 4/4/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

CERT
10.33%
S&P 500 (^GSPC)
13.73%

1-Year Return

CERT
46.20%
S&P 500 (^GSPC)
1.42%

3-Year Return

CERT
57.04%
S&P 500 (^GSPC)
10.72%

5-Year Return

CERT
68.06%
S&P 500 (^GSPC)
103.89%

Compare To: CERT

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: CERT

View More

Valuation Measures

Annual
As of 4/4/2025
  • Market Cap

    1.54B

  • Enterprise Value

    1.67B

  • Trailing P/E

    --

  • Forward P/E

    21.01

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    3.98

  • Price/Book (mrq)

    1.45

  • Enterprise Value/Revenue

    4.34

  • Enterprise Value/EBITDA

    23.08

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -3.13%

  • Return on Assets (ttm)

    0.75%

  • Return on Equity (ttm)

    -1.15%

  • Revenue (ttm)

    385.15M

  • Net Income Avi to Common (ttm)

    -12.05M

  • Diluted EPS (ttm)

    -0.08

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    181.4M

  • Total Debt/Equity (mrq)

    29.46%

  • Levered Free Cash Flow (ttm)

    67.68M

Research Analysis: CERT

View More

Company Insights: CERT

Research Reports: CERT

View More

People Also Watch